Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
50 participants
INTERVENTIONAL
2008-02-29
2008-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison of Two Type of Laryngeal Mask : I-Gel & LMA ProSeal
NCT00624403
Laryngeal Mask Supreme™ Versus the I-gel™
NCT00653237
Comparison Study of Two Supraglottic Airway Devices Used for Patients Under General Anesthesia
NCT01001078
Comparison of Laryngeal Mask and I-gel to Laryngoscope by Novice Operators in Simulated Difficult Airway
NCT02224027
Comparison of the I-gel Laryngeal Mask and the Classic Laryngeal Mask in Patients With a BMI>25
NCT01003327
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The LMA Classic (cLMA) generally provides an adequate airway, but certain problems remain:
1. In 8-33% of LMA placements, more than one attempt is required.
2. It is sometimes difficult to advance the LMA without extending the neck (which is contraindicated in some patients).
3. The device does not protect the airway from aspiration of gastric contents.
4. It does not provide an airtight seal around the larynx (the usual pressures causing leakage of gas being 15-20 cm H20). Consequently, the device may function poorly during positive-pressure ventilation.
5. The esophagus is included within the rim of the LMA in 10-15% of patients, directly exposing the esophagus to positive airway pressures. This often results in insufflation of the stomach and postoperative discomfort.
The LMA Unique (uLMA) is a disposable, inflatable supraglottic airway device that is based on the LMA Classic design which has been used as the "model" in the industry. It has been listed as a commonly accepted device for routine and rescue airway management and is now listed in the American Society of Anesthesiologists (ASA) Difficult Airway Management Algorithm as an airway conduit for tracheal intubation.
The i-gel (Intersurgical Ltd., Wokingham, England) is a cuffless, single-use supraglottic airway device designed to provide a more effective seal than the uLMA, thus eliminating problems 3-5 described above with the addition of a gastric drain. Made of a gel-like thermoplastic elastomer, the i-gel has an anatomically-designed mask that allows quick, easy insertion and can accurately position itself over the laryngeal framework to provide a reliable perilaryngeal seal without the need for an inflatable cuff. In a preliminary study, the peak airway pressures were found to be above 30 cm H2O with a sustained leak pressure of 24 cm H2O versus an average of 18-21 cm H2O seen with the cLMA. According to the 100 patient trial, the i-gel is easier to insert, it has better sealing properties and there is no cuffed inflates.
This clinical study has been designed to compare the i-gel and the uLMA, as to ease of placement, ventilation during mechanical ventilation, proper positioning, seal pressures, the patency of the drain tube, and finally, any complications with their use. Fiberoptic observations through each device will provide information in relation to the epiglottis and the distal opening of the device.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
i-gel-SGA
Patients who received i-gel supraglottic device (i-gel airway) for intubation
i-gel airway (Intersurgical Ltd., Wokingham, England)
supra-glottic airway device
LMA-Unique
Patients who received the Laryngeal Mask Airway-Unique (uLMA) for intubation
Laryngeal Mask Airway-Unique
supra-glottic airway device
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
i-gel airway (Intersurgical Ltd., Wokingham, England)
supra-glottic airway device
Laryngeal Mask Airway-Unique
supra-glottic airway device
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Both male and female patients will be included.
Exclusion Criteria
1. obesity, (BMI \> 35 kg/m2)
2. pregnancy
3. history of gastric regurgitation, heart burn, ileus or "full stomach"
4. history of low pulmonary compliance or high pulmonary resistance
5. known history of difficult endotracheal intubation or signs suggesting the possibility of difficult intubation
6. pharyngeal pathology
7. upper airway obstruction due to laryngeal pathology
18 Years
80 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The University of Texas Health Science Center, Houston
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Carin A. Hagberg
◦Professor and Chairman, Joseph C. Gable, MD Endowed Chair
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Carin A Hagberg, M.D.
Role: PRINCIPAL_INVESTIGATOR
The University of Texas Medical School at Houston
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Memorial Hermann Hospital
Houston, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HSC-MS-08-0004
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.